Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2653-2659

  Bai, Hua ^a   Mao, Li ^a   Wang, Hang Shu ^a   Zhao, Jun ^a   Yang, Lu ^a   An, Tong Tong ^a   Wang, Xin ^a   Duan, Chun Jian ^a   Wu, Na Mei ^a   Guo, Zhi Qing ^a   Liu, Yi Xu ^a   Liu, Hong Ning ^a   Wang, Ye Yu ^a   Wang, Jie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CHINESE; CONTROLLED STUDY; EXON; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; TREATMENT FAILURE; AGED; ASIAN; BLOOD; CHINA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ETHNOLOGY; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; REPRODUCIBILITY; RISK; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DISEASE-FREE SURVIVAL; DNA; DNA, NEOPLASM; EXONS; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 66849091226     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.3930     Document Type: Article

References (24)

1. Shen HB, Yu SZ: Epidemiological status of lung cancer in China and strategies for prevention. Bulletin Chinese Cancer 5:283-285, 2004
2. Parkin DM, Yang L, Li LD, Chen YD: Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China. Chinese J Lung Cancer 4:274-278, 2005
3. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006
4. Franklin WA, Veve R, Hirsch FR, et al: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29:3-14, 2002 (suppl 4)
5. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
6. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
7. Bailey LR, Kris M, Wolf M, et al: Tumor epidermal growth factor receptor (EGFR) expression levels does not predict for response in patients (pts) receiving gefitinib ("Iressa," ZD 1839) monotherapy for pretreated advanced non-small cell lung cancer (NSCLC): IDEAL 1 and 2. Proc Am Assoc Cancer Res 44:1362, 2003 (abstr LB-70)
8. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005
9. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
10. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
11. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
12. Shepherd FA, Pereira JR, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
13. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
14. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
15. Costa DB, Kobayashi S, Tenen DG, et al: Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58:95-103, 2007 16. Sozzi G, Conte D, Leon M, et al: Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902-3908, 2003
16. Sanchez-Cespedes M, Monzo M, Rosell R, et al: Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol 9:113-116, 1998
17. Bruhn N, Beinert T, Oehm C, et al: Detection of Microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann N Y Acad Sci 906:72-82, 2000
18. Esteller M, Sanchez-Cespedes M, Rosell R, et al: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67-70, 1999
19. Kimura H, Suminoe M, Kasahara K, et al: Evaluation of epidermal growth factor receptor mutations in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97:778-784, 2007
20. Moran T, Paz-Ares L, Isla D, et al: High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS). J Clin Oncol 25:June 20, 2007 (suppl)
21. Chin, TM, Anuar D, Soo R, et al: Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem 53:62-70, 2007
22. Cohen V, Agulnik JS, Jarry J, et al: Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in non-small-cell lung cancer. Cancer 107:2858-2865, 2006
23. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004
24. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III Trial - INTACT 2. J Clin Oncol 22:785-794, 2004